PDCD1 and colorectal cancer: However, still, approximately 60% of MSI colorectal cancer patients do not respond to single immune checkpoint inhibitor treatment such as anti-PD1, and approximately 40% of MSI colorectal patients do not respond to combinations of immune checkpoint inhibitor treatment (Oliveira et al., 2019).